Godavari Biorefineries Limited has informed the Exchange about Transcript
GODAVARIB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Biorefineries reported Q1 FY26 revenue of INR533.2 crores (up from INR522.5 crores YoY) with a positive EBITDA of INR6.5 crores, a turnaround from a loss in the same quarter last year, and an improvement of INR16 crores. Gross margin expanded by 512 basis points to 19%, and the bio-based specialty chemicals segment saw a 43% increase in EBITDA. Management reaffirmed a 3x EBITDA target by FY29, driven by a 200 KLPD maize-based ethanol distillery set to commission by end of calendar year 2025 (potential revenue of INR400+ crores at current prices) and de-bottlenecking in specialty chemicals. A further capex of INR325 crores has been identified (70% for bio-based specialty chemicals, 30% for ethanol). On the drug discovery front, a novel anti-cancer molecule received European patent validation with safety trials concluded, though commercialization or out-licensing is still 2-3 years away.
Constructive operational turnaround with multiple visible growth catalysts through FY29. The reaffirmed 3x EBITDA target and clear commissioning timelines for the maize distillery could support positive investor sentiment, though the company remains loss-making at the PBT level (negative INR22.3 crores) and execution risk on capex and drug pipeline remains.